Improving protein production to treat cystic fibrosis
Official title: Tuning translation efficiency to overcome refractory defects in CFTR
Funded at Emory University · NIH-11050617 · Data updated 2026-11-12
This study is looking at ways to help people with cystic fibrosis by finding new treatments that boost the production of a key protein, especially for those with tough-to-treat genetic mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | February 1, 2025 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $629,319 |
| NIH project number | 1R01HL173500-01A1 |
| Project ID | NIH-11050617 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those with specific mutations in the CFTR gene that lead to severe disease.
✕Less likely to help
Patients with cystic fibrosis who do not have mutations in the CFTR gene or those whose condition is not related to translation efficiency may not benefit from this research.
What this research studies
This research focuses on cystic fibrosis (CF), a genetic disorder caused by mutations in the CFTR gene. The team aims to enhance the production of the CFTR protein by targeting specific ribosomal proteins that influence how the protein is made. By understanding how these proteins can be manipulated, the researchers hope to develop new therapies for patients with CF, particularly those with severe mutations that current treatments do not address. The approach involves both laboratory studies and potential applications in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the health and quality of life for patients with cystic fibrosis.
How similar studies have gone: Previous research has shown promise in manipulating ribosomal proteins to improve protein function, indicating that this approach may be effective for treating cystic fibrosis.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Oliver, Kathryn E — Emory University
- Study coordinator: Oliver, Kathryn E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.